Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2022-11-09 | 2022-09 | -0.42 | N/A | N/A | N/A |
2022-08-08 | 2022-06 | -0.42 | N/A | N/A | N/A |
2022-05-04 | 2022-03 | -0.43 | N/A | N/A | N/A |
2022-02-23 | 2021-12 | -0.6 | N/A | N/A | N/A |
2021-11-03 | 2021-09 | -0.48 | N/A | N/A | N/A |
2021-08-04 | 2021-06 | -0.57 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2022-11-10 | JP Morgan | Downgrade | Neutral | Underweight |
2022-05-06 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
2022-05-05 | HC Wainwright & Co. | Upgrade | Buy | |
2021-09-21 | HC Wainwright & Co. | Upgrade | Buy | |
2021-08-05 | HC Wainwright & Co. | Upgrade | Buy | |
2021-05-05 | HC Wainwright & Co. | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2022-11-01 | GROSS PAUL EDWARD | General Counsel | 98.33K | Sale |
2022-11-01 | HARDING THOMAS C | Officer | 0.00 | Sale |
2022-11-01 | IVERS-READ GILLIAN C | Officer | 293.61K | Sale |
2022-11-01 | MUEHL DANIEL W | Chief Financial Officer | 104.83K | Sale |
2022-11-01 | ROLFE LINDSEY | Officer | 113.69K | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-09-29 | Vanguard Group, Inc. (The) | 10.21M | 828.77K | 7.04% |
2022-09-29 | Palo Alto Investors Lp | 4.47M | 363.29K | 3.09% |
2022-09-29 | Blackrock Inc. | 4.04M | 327.67K | 2.78% |
2022-09-29 | QVT Financial LP | 3.53M | 286.23K | 2.43% |
2022-09-29 | Renaissance Technologies, LLC | 2.21M | 179.43K | 1.52% |
2022-09-29 | Geode Capital Management, LLC | 1.38M | 112.30K | 0.95% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-09-29 | Vanguard Total Stock Market Index Fund | 4.34M | 352.67K | 3.00% |
2022-09-29 | Vanguard Extended Market Index Fund | 1.92M | 155.70K | 1.32% |
2022-09-29 | Vanguard Strategic Equity Fund | 1.68M | 136.34K | 1.16% |
2022-07-30 | Vanguard Explorer Fund, Inc. | 1.44M | 116.87K | 0.99% |
2022-11-29 | iShares NASDAQ Biotechnology ETF | 1.17M | 94.72K | 0.80% |
2022-10-30 | Fidelity Extended Market Index Fund | 747.38K | 60.69K | 0.52% |
-
$MART. Enjoy.!! Thank a lot. For the TIPS. Have nice Weekend.
-
Going’s to green
-
Clovis Oncology (NASDAQ:CLVS) to Post FY2024 Earnings of ($0.04) Per Share, Piper Sandler Forecasts
Posted by Clara Ruiz on Jan 9th, 2020
Clovis Oncology logo
Clovis Oncology (NASDAQ:CLVS) – Equities researchers at Piper Sandler issued their FY2024 earnings per share estimates for Clovis Oncology in a research note issued on Tuesday, January 7th. Piper Sandler analyst J. Catanzaro forecasts that the biopharmaceutical company will post earnings of ($0.04) per share for the year. -
Tk’s MAR$9. For News.
-
It's coming the best!! The plate. The good news of the Aprobación SNDA. + jp Morgan conference - MONDAY + Revenues And EPS. Projection $26. believe it!! Enjoy
-
$SMART.... You are “The Best”. The Best is COMING. Really....
-
I support you!!!
$MART$9X.
Projection $22 or 23. Soon. -
I Don’t understand!!! What’s going on this Share. ???
-
-
This action is a fake and has the full potential to climb up to a good price.
-
A full potential!!! And he doesn't get up. Shit
-
Me Too!!! I Don’t Understand. Really.....
-
-
When?? $CLVS. When...
-
-
-
It has good news and excellent approvals are afraid.
-
It has good news and excellent approvals are afraid.
-
It has good news and excellent approvals are afraid.
-
I don't understand why this action bullshit doesn t start.